Showing results (301-310 of 331) with videos related to

Sort By:
Pageof 34
The Journal of Biological Chemistry|June 17, 2015
Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced NeurodegenerationJoão P L Daher, Hisham A Abdelmotilib, Xianzhen Hu, et al.
NPJ Parkinson'S Disease|August 11, 2023
Transient exposure to rotenone causes degeneration and progressive parkinsonian motor deficits, neuroinflammation, and synucleinopathyAmber D Van Laar, Katherine R Webb, Matthew T Keeney, et al.
Bioorganic & Medicinal Chemistry Letters|August 13, 2014
Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffoldPaul Galatsis, Jaclyn L Henderson, Bethany L Kormos, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|February 13, 2001
The C-terminal domains of the GABA(b) receptor subunits mediate intracellular trafficking but are not required for receptor signalingA R Calver, M J Robbins, C Cosio, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|July 15, 2016
G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in NeuronsLaura A Volpicelli-Daley, Hisham Abdelmotilib, Zhiyong Liu, et al.
Plos One|August 8, 2025
Expression of human A53T alpha-synuclein without endogenous rat alpha-synuclein fails to elicit Parkinson's disease-related phenotypes in a novel humanized rat modelNicole K Polinski, Jukka Puoliväli, Leena Rauhala, et al.
Biophysical Journal|April 23, 2010
Assembly pathway of a designed alpha-helical protein fiberElizabeth H C Bromley, Kevin J Channon, Patrick J S King, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 24, 2025
Comparative assessment of binding and functional differences of clinical antibodies targeting α-synuclein in cellular models of Parkinson's diseaseYuTing Liu, Isin Dalkilic-Liddle, You Li, et al.
Polymer Chemistry|November 10, 2022
N-Hydroxyethyl acrylamide as a functional eROP initiator for the preparation of nanoparticles under "greener" reaction conditionsJoachim C Lentz, Robert Cavanagh, Cara Moloney, et al.
British Journal of Pharmacology|November 18, 2000
The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofenM D Wood, K L Murkitt, S Q Rice, et al.
Pageof 34